[1]
|
Large, V., Peroni, O., Letexier, D., Ray, H. and Beylot, M. (2004) Metabolism of Lipids in Human White Adipocyte. Diabetes & Metabolism, 30, 294-309. https://doi.org/10.1016/S1262-3636(07)70121-0
|
[2]
|
Wolin, K.Y., Carson, K. and Colditz, G.A. (2010) Obesity and Cancer. Oncologist, 15, 556-565. https://doi.org/10.1634/theoncologist.2009-0285
|
[3]
|
Vance, J.E. and Vance, D. (2008) Biochemistry of Lipids, Lipoproteins and Membranes. 5th Edition, Elsevier, Amsterdam, 8-9.
|
[4]
|
Mattes, R.D. (2005) Fat Taste and Lipid Metabolism in Humans. Physiology & Behavior, 86, 691-697. https://doi.org/10.1016/j.physbeh.2005.08.058
|
[5]
|
Zechner, R., Zimmermann, R., Eichmann, T.O., Kohlwein, S.D., Haemmerle, G., Lass, A. and Madeo, F. (2012) Fat Signals—Lipases and Lipolysis in Lipid Metabolism and Signaling. Cell Metabolism, 15, 279-291. https://doi.org/10.1016/j.cmet.2011.12.018
|
[6]
|
Fahy, E., Cotter, D., Sud, M. and Subramaniam, S. (2011) Lipid Classification, Structures and Tools. Biochim et Biophys Acta: Molecular and Cell Biology of Lipids, 1811, 637-647. https://doi.org/10.1016/j.bbalip.2011.06.009
|
[7]
|
Santos, C.R. and Schulze, A. (2012) Lipid Metabolism in Cancer. The FEBS Journal, 279, 2610-2623. https://doi.org/10.1111/j.1742-4658.2012.08644.x
|
[8]
|
Hsu, P.P. and Sabatini, D.M. (2008) Cancer Cell Metabolism: Warburg and Beyond. Cell, 134, 703-707. https://doi.org/10.1016/j.cell.2008.08.021
|
[9]
|
Menendez, J.A. and Lupu, R. (2007) Fatty Acid Synthase and the Lipogenic Phenotype in Cancer Pathogenesis. Nature Reviews Cancer, 7, 763-777. https://doi.org/10.1038/nrc2222
|
[10]
|
Zaidi, N., Lupien, L., Kuemmerle, N.B., Kinlaw, W.B., Swinnen, J.V. and Smans, K. (2013) Lipogenesis and Lipolysis: The Pathways Exploited by the Cancer Cells to Acquire Fatty Acids. Progress in Lipid Research, 52, 585-589. https://doi.org/10.1016/j.plipres.2013.08.005
|
[11]
|
Hegele, R.A. (2009) Plasma Lipoproteins: Genetic Influences and Clinical Implications. Nature Reviews Genetics, 10, 109-121. https://doi.org/10.1038/nrg2481
|
[12]
|
Grundy, S.M. (2004) Obesity, Metabolic Syndrome, and Cardiovascular Disease. The Journal of Clinical Endocrinology & Metabolism, 89, 2595-2600. https://doi.org/10.1210/jc.2004-0372
|
[13]
|
Munir, R., Usman, H., Hasnain, S., Smans, K., Kalbacher, H. and Zaidi, N. (2014) Atypical Plasma Lipid Profile in Cancer Patients: Cause or Consequence. Biochinie, 102, 9-18. https://doi.org/10.1016/j.biochi.2014.03.010
|
[14]
|
Mantovani, A., Allavena, P., Sica, A. and Balkwill, F. (2008) Cancerrelated Inflammation. Nature, 454, 436-444. https://doi.org/10.1038/nature07205
|
[15]
|
Coussens, L.M. and Werb, Z. (2002) Inflammation and Cancer. Nature, 420, 860-867. https://doi.org/10.1038/nature01322
|
[16]
|
Alexandrov, L.B., Nik-Zainal, S., Wedge, D., Aparicio, S.A., Behjati, S., Biankin, A.V., et al. (2013) Signatures of Mutational Processes in Human Cancer. Nature, 500, 415-421. https://doi.org/10.1038/nature12477
|
[17]
|
Iyengar, N.M., Hudis, C.A. and Dannenberg, A.J. (2015) Obesity and Cancer: Local and Systemic Mechanisms. Annual Review of Medicine, 66, 297-309. https://doi.org/10.1146/annurev-med-050913-022228
|
[18]
|
Lengauer, C., Kinzler, K.W. and Vogelstein, B. (1998) Genetic Instabilities in Human Cancers. Nature, 396, 643-649. https://doi.org/10.1038/25292
|
[19]
|
Stephens, P.J., Greenman, C.D., Fu, B., Yang, F., Bignell, G.R., Mudie, L.J., et al. (2011) Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development. Cell, 144, 27-40.
|
[20]
|
Sansregret, L., Vanhaesebroeck, B. and Swanton, C. (2018) Determinants and Clinical Implications of Chromosomal Instability in Cancer. Nature Reviews Clinical Oncology, 15, 139-150. https://doi.org/10.1038/nrclinonc.2017.198
|
[21]
|
Jain, R.K. (2005) Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science, 307, 58-62. https://doi.org/10.1126/science.1104819
|
[22]
|
Minchinton, A.I. and Tannock, I.F. (2006) Drug Penetration in Solid Tumours. Nature Reviews Cancer, 6, 583-592. https://doi.org/10.1038/nrc1893
|
[23]
|
Goldie, J.H. and Coldman, A.J. (1984) The Genetic Origin of Drug Resistance in Neoplasms: Implications for Systemic Therapy. Cancer Research, 44, 3643-3653.
|
[24]
|
Fisher, B., Slack, N.H. and Bross, I.D. (1969) Cancer of the Breast: Size of Neoplasm and Prognosis. Cancer, 24, 1071-1080. https://doi.org/10.1002/1097-0142(196911)24:5<1071::AID-CNCR2820240533>3.0.CO;2-H
|
[25]
|
Skipper, H.E., Schabel Jr., F.M. and Wilcox, W.S. (1964) Experimental Evaluation of Potential Anticancer Agents. XIII. On the Criteria and Kinetics Associated with “Curability” of Experimental Leukemia. Cancer Chemotherapy Reports, 35, 1-111.
|
[26]
|
Sharma, P., Hu-Lieskovan, S., Wargo, J.A. and Ribas, A. (2017) Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 168, 707-723. https://doi.org/10.1016/j.cell.2017.01.017
|
[27]
|
Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J., Sodir, N.M., et al. (2008) Modelling Myc Inhibition as a Cancer Therapy. Nature, 455, 679-683. https://doi.org/10.1038/nature07260
|
[28]
|
Ostrem, J.M., Peters, U., Sos, M.L., Wells, J.A. and Shokat, K.M. (2013) K-Ras(G12C) Inhibitors Allosterically Control GTP Affinity and Effector Interactions. Nature, 503, 548-551. https://doi.org/10.1038/nature12796
|
[29]
|
Lambert, J.M., Gorzov, P., Veprintsev, D.B.,Söderqvist, M., Segerbäck, D., Bergman, J., et al. (2009) PRIMA-1 Reactivates Mutant P53 by Covalent Binding to the Core Domain. Cancer Cell, 15, 376-388. https://doi.org/10.1016/j.ccr.2009.03.003
|
[30]
|
Timovska, Y., Pivnyuk, V., Todor, I., Anikusko, N. and Chekhun, V. (2011) The Spectrum of Blood Serum Lipids in Patients with Breast Cancer without Metabolic Syndrome. Experimental Oncology, 33, 190-192.
|
[31]
|
Agurs-Collins, T., Kim, K.S., Dunston, G.M. and Adams-Campbell, L.L. (1998) Plasma Lipid Alterations in African-American Women with Breast Cancer. Journal of Cancer Research and Clinical Oncology, 124, 186-190. https://doi.org/10.1007/s004320050153
|
[32]
|
Delimaris, I., Faviou, E., Antonakos, G., Stathopoulou, E., Zachari, A. and Dionyssiou-Asteriou, A. (2007) Oxidized LDL, Serum Oxidizability and Serum Lipid Levels in Patients with Breast or Ovarian Cancer. Clinical Biochemistry, 40, 1129-1134. https://doi.org/10.1016/j.clinbiochem.2007.06.007
|
[33]
|
Abdelsalam, K.E., Hassan, I.K. and Sadig, I.A. (2012) The Role of Developing Breast Cancer in Alteration of Serum Lipid Profile. Journal of Research in Medical Sciences 17, 562-565.
|
[34]
|
Bhat, S.A., Mir, M.R., Majid, S., Reshi, A.A., Husain, I., Hassan, T. and Ahmad, H. (2013) Serum Lipid Profile of Breast Cancer Patients in Kashmir. American Journal of Physiology, Biochemistry and Pharmacology, 2, 26-31. https://doi.org/10.5455/jib.20121125075314
|
[35]
|
Hasija, K. and Bagga, H.K. (2005) Alterations of Serum Cholesterol and Serum Lipoprotein in Breast Cancer of Women. Indian Journal of Clinical Biochemistry, 20, 61-66. https://doi.org/10.1007/BF02893044
|
[36]
|
Liu, Y.L., Qian, H.X., Qin, L., Zhou, X.J., Zhang, B. and Chen, X. (2012) Association of Serum Lipid Profile with Distant Metastasis in Breast Cancer Patients. Chinese Journal of Oncology, 34, 129-131
|
[37]
|
Bahl, M., Ennis, M., Tannock, I.F., Hux, J.E., Pritchard, K.I., Koo, J. and Goodwin, P.J. (2005) Serum Lipids and Outcome of Early-Stage Breast Cancer: Results of a Prospective Cohort Study. Breast Cancer Research and Treatmen, 94, 135-144. https://doi.org/10.1007/s10549-005-6654-9
|
[38]
|
Eliassen, A.H., Colditz, G.A., Rosner, B., Willett, W.C. and Hankinson, S.E. (2005) Serum Lipids, Lipid-Lowering Drugs, and the Risk of Breast Cancer. Archives of Internal Medicine, 165, 2264-2271. https://doi.org/10.1001/archinte.165.19.2264
|
[39]
|
Thangaraju, M., Kumar, K., Gandhirajan, R. and Sachdanandam, P. (1994) Effect of Tamoxifen on Plasma Lipids and Lipoproteins in Postmenopausal Women with Breast Cancer. Cancer, 73, 659-663. https://doi.org/10.1002/1097-0142(19940201)73:3<659::AID-CNCR2820730325>3.0.CO;2-H
|
[40]
|
Knapp, M., Al-Sheibani, S. and Riches, P. (1991) Alterations of Serum Lipids in Breast Cancer: Effects of Disease Activity, Treatment, and Hormonal Factors. Clinical Chemistry, 37, 2093-2101. https://doi.org/10.1093/clinchem/37.12.2093
|
[41]
|
Hoyer, A.P. and Engholm, G. (1992) Serum Lipids and Breast Cancer Risk: A Cohort Study of 5,207 Danish Women. Cancer Causes & Control, 3, 403-408. https://doi.org/10.1007/BF00051352
|
[42]
|
Laisupasin, P., Thompat, W., Sukarayodhin, S., Sornprom, A. and Sudjaroen, Y. (2013) Comparison of Serum Lipid Profiles between Normal Controls and Breast Cancer Patients. Journal of Laboratory Physicians, 5, 38-41. https://doi.org/10.4103/0974-2727.115934
|
[43]
|
Furberg, A.S., Jasienska, G., Bjurstam, N., Torjesen, P.A., Emaus, A., Lipson, S.F., Ellison, P.T. and Thune, I. (2005) Metabolic and Hormonal Profiles: HDL Cholesterol as a Plausible Biomarker of Breast Cancer Risk. Cancer Epidemiology, Biomarkers & Prevention, 14, 33-40.
|
[44]
|
Furberg, A.S., Veierod, M.B., Wilsgaard, T., Bernstein, L. and Thune, I. (2004) Serum Highdensity Lipoprotein Cholesterol, Metabolic Profile, and Breast Cancer Risk. JNCI: Journal of the National Cancer Institute, 96, 1152-1160. https://doi.org/10.1093/jnci/djh216
|
[45]
|
Lindemann, K., Vatten, L.J., Ellstrom-Engh, M. and Eskild, A. (2009) Serum Lipids and Endometrial Cancer Risk: Results from the HUNT-II Study. International Journal of Cancer, 124, 2938-2941. https://doi.org/10.1002/ijc.24285
|
[46]
|
Seth, D., Garmo, H., Wigertz, A., Holmberg, L., Hammar, N., Jungner, I., Lambe, M., Walldius, G. and Van Hemelrijck, M. (2012) Lipid Profiles and the Risk of Endometrial Cancer in the Swedish AMORIS Study. International Journal of Molecular Epidemiology and Genetics, 3, 122-133.
|
[47]
|
Allott, E., Howard, L., Cooperberg, M.R., Kane, C., Aronson, W.J., Terris, M., Amling, C. and Freedland, S. (2014) Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiology, Biomarkers & Prevention, 23, 2349-2356. https://doi.org/10.1158/1055-9965.EPI-14-0458
|
[48]
|
Salgado-Montilla, J., Salgado, M., Trautmann, B., Sánchez-Ortiz, R. and Irizarry-Ramírez, M. (2015) Association of Serum Lipid Levels and Prostate Cancer Severity among Hispanic Puerto Rican Men. Lipids in Health and Disease, 14, Article No. 111. https://doi.org/10.1186/s12944-015-0096-0
|
[49]
|
Zhang, G., Qin, X.J., Zhang, H.L., Xiao, W.J., Zhu, Y., Gu, C.Y., Dai, B., Shi, G.H. and Ye, D.W. (2015) Serum Lipid Profiles: Novel Biomarkers Predicting Advanced Prostate Cancer in Patients Receiving Radical Prostatectomy. Asian Journal of Andrology, 17, 239-244. https://doi.org/10.4103/1008-682X.142135
|
[50]
|
Qiming, S.C., Ding, Z.G. and Li, G. (2019) Influence of Serum Total Cholesterol, LDL, HDL, and Triglyceride on Prostate Cancer Recurrence after Radical Prostatectomy. Cancer Management and Research, 11, 6651-6661. https://doi.org/10.2147/CMAR.S204947
|
[51]
|
Siemianowicz, K., Gminski, J., Stajszczyk, M., Wojakowski, W., Goss, M., Machalski, M., Telega, A., Brulinski, K. and Magiera-Molendowska, H. (2000) Serum HDL Cholesterol Concentration in Patients with Squamous Cell and Small Cell Lung Cancer. International Journal of Molecular Medicine, 6, 307-318. https://doi.org/10.3892/ijmm.6.3.307
|
[52]
|
Siemianowicz, K., Gminski, J., Stajszczyk, M., Wojakowski, W., Goss, M., Machalski, M., Telega, A., Brulinski, K. and Magiera-Molendowska, H. (2000) Serum Total Cholesterol and Triglycerides Levels in Patients with Lung Cancer. International Journal of Molecular Medicine, 5, 201-205. https://doi.org/10.3892/ijmm.5.2.201
|
[53]
|
Siemianowicz, K., Gminski, J., Stajszczyk, M., Wojakowski, W., Goss, M., Machalski, M., Telega, A., Brulinski, K. and Magiera-Molendowska, H. (2000) Serum LDL Cholesterol Concentration and Lipoprotein Electrophoresis Pattern in Patients with Small Cell Lung Cancer. International Journal of Molecular Medicine, 5, 55-62. https://doi.org/10.3892/ijmm.5.1.55
|
[54]
|
Zhan, C.-Z., Zhao, X.-W., Liu, D.-B., Han, C.-Z., Du, L.-L. and Jing, J.-X. (2014) Lipid Levels in Serum and Cancerous Tissues of Colorectal Cancer Patients. World Journal of Gastroenterology, 20, 8646-8652. https://doi.org/10.3748/wjg.v20.i26.8646
|
[55]
|
Iso, H., Ikeda, A., Inoue, M., Sato, S. and Tsugane, S. (2009) Serum Cholesterol Levels in Relation to the Incidence of Cancer: The JPHC Study Cohorts. International Journal of Cancer, 125, 2679-2686. https://doi.org/10.1002/ijc.24668
|
[56]
|
Brantleya, K., Riisc, A., Erichsenc, R., Thorlacius-Ussinge, O., Jon Møllerf, H. and Lasha, T. (2020) the Association of Serum Lipid Levels with Colorectal Cancer Recurrence. Cancer Epidemiology, 66, Article ID: 101725. https://doi.org/10.1016/j.canep.2020.101725
|
[57]
|
Chandler, P.D., Song, Y., Lin, L., Zhang, S., Sesso, H.D. and Mora, S. (2016) Lipid Biomarkers and Long-Term Risk of Cancer in the Women’s Health Study. The American Journal of Clinical Nutrition, 6, 1397-1407. https://doi.org/10.3945/ajcn.115.124321
|
[58]
|
Yang, M.H., Rampal, S., Sung, J., Choi, Y.-H., Son, H.J., Lee, J.H., Kim, Y.H., Chang, D.K., Rhee, P-L. and Kim, J.J. (2013) the Association of Serum Lipids with Colorectal Adenomas. American Journal of Gastroenterology, 108, 833-841. https://doi.org/10.1038/ajg.2013.64
|
[59]
|
Lippi, G., Franchini, M., Salvagno, G.L. and Guidi, G.C. (2007) Lipoprotein[a] and Cancer: Anti-Neoplastic Effect besides Its Cardiovascular Potency. Cancer Treatment Reviews, 33, 427-436. https://doi.org/10.1016/j.ctrv.2007.02.006
|
[60]
|
Leibundgut, G., Scipione, C., Yin, H., Schneider, M., Boffa, M.B., Green, S., Yang, X., Dennis, E., Witztum, J.L., Koschinsky, M.L. and Tsimikas, S. (2013) Determinants of Binding of Oxidized Phospholipids on Apolipoprotein (a) and Lipoprotein (a). Journal of Lipid Research, 54, 2815-2830. https://doi.org/10.1194/jlr.M040733
|
[61]
|
Orso, E. and Schmitz, G. (2017) Lipoprotein(a) and Its Role in Inflammation, Atherosclerosis and Malignancies. Clinical Research in Cardiology Supplements, 12, 31-37. https://doi.org/10.1007/s11789-017-0084-1
|
[62]
|
Constans, J., Wendling, G., Peuchant, E., Camilleri, G. and Conri, C. (1996) Lipoprotein(a) in 505 Hospitalized Patients with Various Pathological States: Correlations with Cardiovascular Diseases and Therapies. International Angiology, 15, 1-5.
|
[63]
|
Wang, M. and Zhang, Y. (2019) High Lipoprotein(a) Level Is Independently Associated with Adverse Clinicopathological Features in Patients with Prostate. Dis Markers, 2019, Article ID: 9483935. https://doi.org/10.1155/2019/9483935
|
[64]
|
Marrera, M., Wagnera, A., Le Montayed, M., Luce, G., Amouyel, P., Dallongeville, J., Ducimetiere, P., Bingham, A., Arveiler, D. and Veltena, M. (2013) Lipoprotein(a) Plasma Levels and the Risk of Cancer: The PRIME Study. European Journal of Cancer Prevention, 22, 286-293. https://doi.org/10.1097/CEJ.0b013e328359cba7
|
[65]
|
Motta, M., Giugno, I., Ruello, P., Pistone, G., Di Fazio, I. and Malaguarnera, M. (2001) Lipoprotein(a) Behaviour in Patients with Hepatocellular Carcinoma. Minerva Medica, 92, 301-305.
|
[66]
|
Jiang, J., Nilsson-Ehle, P. and Xu, N. (2006) Influence of Liver Cancer on Lipid and Lipoprotein Metabolism. Lipids in Health and Disease, 5, Article No. 4. https://doi.org/10.1186/1476-511X-5-4
|
[67]
|
Xu, J., Qiu, X., Li, Y., Sun, N., Zhang, Y. and Shu, J. (2020) Hyperlipoproteinemia (a) Is Associated with Breast Cancer in a Han Chinese Population. Medicine, 99, Article No. e22037. https://doi.org/10.1097/MD.0000000000022037
|
[68]
|
Sawabe, M., Tanaka, N. and Mieno, M.N. (2012) Low Lipoprotein(a) Concentration Is Associated with Cancer and All-Cause Deaths: A Population-Based Cohort Study. PLoS ONE, 7, Article ID: e31954. https://doi.org/10.1371/journal.pone.0031954
|
[69]
|
Kokoglu, E., Karaarslan, I. and Karaarslan, H.M. (1994) Elevated Serum Lp(a) Levels in the Early and Advanced Stages of Breast Cancer. Cancer Biochemistry Biophysics, 14, 133-136.
|
[70]
|
Kuesel, A.C., Kroft, T., Prefontaine, M. and Smith, I.C. (1992) Lipoprotein(a) and CA125 Levels in the Plasma of Patients with Benign and Malignant Ovarian Disease. International Journal of Cancer, 52, 341-346. https://doi.org/10.1002/ijc.2910520302
|
[71]
|
Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S. and Lazar, M.A. (2001) the Hormone Resistin Links Obesity to Diabetes. Nature, 409, 307-312. https://doi.org/10.1038/35053000
|
[72]
|
Savage, D.B., Sewter, C.P., Klenk, E.S., Segal, D.G., Vidal-Puig, A., Considine, R.V. and O’Rahilly, S. (2001) Resistin/Fizz3 Expression in Relation to Obesity and Peroxisome Proliferator-Activated Receptor-γ Action in Humans. Diabetes, 50, 2199-2202. https://doi.org/10.2337/diabetes.50.10.2199
|
[73]
|
Lehrke, M., Reilly, M.P., Millington, S.C., Iqbal, N., Rader, D.J. and Lazar, M.A. (2004) An Inflammatory Cascade Leading to Hyperresistinemia in Humans. PLoS Medicine, 1, Article No. e45. https://doi.org/10.1371/journal.pmed.0010045
|
[74]
|
Danese, E., Montagnana, M., Minicozzi, A.M., Bonafini, S., Ruzzenente, O., Gelati, M., De Manzoni, G., Lippi, G. and Guidi, G.C. (2012) The Role of Resistin in Colorectal Cancer. Clinica Chimica Acta, 413, 760-764. https://doi.org/10.1016/j.cca.2012.01.019
|
[75]
|
Assiri, A.M., Kamel, H.F. and Hassanien, M.F. (2015) Resistin, Visfatin, Adiponectin, and Leptin: Risk of Breast Cancer in Pre- and Postmenopausal Saudi Females and Their Possible Diagnostic and Predictive Implications as Novel Biomarkers. Disease Markers, 2015, Article ID: 253519, 9 Pages. https://doi.org/10.1155/2015/253519
|
[76]
|
Assiri, A.M. and Kamel, H.F. (2016) Evaluation of Diagnostic and Predictive Value of Serum Adipokines: Leptin, Resistin and Visfatin in Postmenopausal Breast Cancer. Obesity Research & Clinical Practice, 10, 442-453. https://doi.org/10.1016/j.orcp.2015.08.017
|
[77]
|
Kang, J.H., Yu, B.Y. and Youn, D.S. (2007) Relationship of Serum Adiponectin and Resistin Levels with Breast Cancer Risk. Journal of Korean Medical Science, 22, 117-121. https://doi.org/10.3346/jkms.2007.22.1.117
|
[78]
|
Dalamaga, M., Karmaniolas, K., Papadavid, E., Pelekanos, N., Sotiropoulos, G. and Lekka, A. (2013) Hyperresistinemia Is Associated with Postmenopausal Breast Cancer. Menopause, 20, 845-851. https://doi.org/10.1097/GME.0b013e31827f06dc
|
[79]
|
Gunter, M.J., Wang, T., Cushman, M., Xue, X., Wassertheil-Smoller, S., Strickler, H.D., Rohan, T.E., Manson, J.E., McTiernan, A., Kaplan, R.C., Scherer, P.E., Chlebowski, R.T., Snetselaar, L., Wang, D. and Ho, G.Y. (2015) Circulating Adipokines and Inflammatory Markers and Postmenopausal Cancer Risk. JNCI: Journal of the National Cancer Institute, 107, djv169. https://doi.org/10.1093/jnci/djv169
|
[80]
|
Mu~noz-Palomeque, A., Guerrero-Ramirez, M.A., Rubio-Chavez, L.A., Rosales-Gomez, R.C., Lopez-Cardona, M.G., Barajas-Avila, V.H., Delgadillo-Barrera, A., Canton-Romero, J.C., Montoya-Fuentes, H., Garcia-Cobian, T.A. and Gutierrez-Rubio, S.A. (2018) Association of RETN and CAP1 SNPs, Expression and Serum Resistin Levels with Breast Cancer in Mexican Women. Genetic Testing and Molecular Biomarkers, 22, 209-217. https://doi.org/10.1089/gtmb.2017.0212
|
[81]
|
Crisostomo, P., Matafome, D., Santos-Silva, A.L., Gomes, M., Gomes, M., Patricio, L., Letra, A.B., Sarmento-Ribeiro, L. and Seica, S.R. (2016) Hyperresistinemia and Metabolic Dysregulation: A Risky Crosstalk in Obese Breast Cancer. Endocrine, 53, 433-442. https://doi.org/10.1007/s12020-016-0893-x
|
[82]
|
Salageanu, A., Tucureanu, C. and Lerescu, L. (2010) Serum Levels of Adipokines Resistin and Leptin in Patients with Colon Cancer. Journal of Medicine and Life, 3, 416-420.
|
[83]
|
Nakajima, T.E., Yamada, Y. and Hamano, T. (2010) Adipocytokines as New Promising Markers of Colorectal Tumors: Adiponectin for Colorectal Adenoma, and Resistin and Visfatin for Colorectal Cancer. Cancer Science, 101, 1286-1291. https://doi.org/10.1111/j.1349-7006.2010.01518.x
|
[84]
|
Gonullu, G., Kahraman, H., Bedir, A., Bektas, A. and Yucel, I. (2010) Association between Adiponectin, Resistin, Insulin Resistance, and Colorectal Tumors. International Journal of Colorectal Disease, 25, 205-212. https://doi.org/10.1007/s00384-009-0828-6
|
[85]
|
Diakowska, D., Markocka-Mdczka, K., Szelachowski, P. and Grabowski, K. (2014) Serum Levels of Resistin, Adiponectin, and Apelin in Gastroesophageal Cancer Patients. Disease Markers, 2014, Article ID: 619649. https://doi.org/10.1155/2014/619649
|
[86]
|
Samal, B., Sun, Y., Stearns, G., Xie, C., Suggs, S. and McNiece, I. (1994) Cloning and Characterization of the CDNA Encoding a Novel Human Pre-B-Cell Colony-Enhancing Factor. Molecular and Cellular Biology, 14, 1431-1437. https://doi.org/10.1128/mcb.14.2.1431-1437.1994
|
[87]
|
Preiss, J. and Handler, P. (1957) Enzymatic Synthesis of Nicotinamide Mononucleotide. Journal of Biological Chemistry, 225, 759-770. https://doi.org/10.1016/S0021-9258(18)64875-6
|
[88]
|
Rongvaux, A., Shea, R.J., Mulks, M.H., Gigot, D., Urbain, J., Leo, O. and Andris, F. (2002) Pre-B-Cell Colony-Enhancing Factor, Whose Expression Is Up-Regulated in Activated Lymphocytes, Is a Nicotinamide Phosphoribosyltransferase, a Cytosolic Enzyme Involved in NAD Biosynthesis. European Journal of Immunology, 32, 3225-3234. https://doi.org/10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L
|
[89]
|
Luk, T., Malam, Z. and Marshall, J.C. (2008) Pre-B Cell Colony-Enhancing Factor (PBEF)/Visfatin: A Novel Mediator of Innate Immunity. Journal of Leukocyte Biology, 83, 804-816. https://doi.org/10.1189/jlb.0807581
|
[90]
|
Murphy, K.G. and Bloom, S.R. (2006) Are All Fats Created Equal. Nature Medicine, 12, 32-33. https://doi.org/10.1038/nm0106-32
|
[91]
|
Revollo, J.R., Grimm, A.A. and Imai, S. (2004) the NAD Biosynthesis Pathway Mediated by Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells. Journal of Biological Chemistry, 279, 50754-50763. https://doi.org/10.1074/jbc.M408388200
|
[92]
|
Curat, C.A., Wegner, V., Sengenes, C., Miranville, A., Tonus, C., Busse, R. and Bouloumie, A. (2006) Macrophages in Human Visceral Adipose Tissue: Increased Accumulation in Obesity and a Source of Resistin and Visfatin. Diabetologia, 49, Article No. 744. https://doi.org/10.1007/s00125-006-0173-z
|
[93]
|
Boucher, J., Masri, B., Daviaud, D., Gesta, S., Guigne, C., Mazzucotelli, A., Castan-Laurell, I., Tack, I., Knibiehler, B., Carpene, C., Audigier, Y., Saulnier-Blache, J.S. and Valet, P. (2005) Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity. Endocrinology, 146, 1764-1771. https://doi.org/10.1210/en.2004-1427
|
[94]
|
Berndt, J., Kloting, N., Kralisch, S., Kovacs, P., Fasshauer, M., Schon, M.R., Stumvoll, M. and Bluher, M. (2005) Plasma Visfatin Concentrations and Fat Depot-Specific MRNA Expression in Humans. Diabetes, 54, 2911-2916. https://doi.org/10.2337/diabetes.54.10.2911
|
[95]
|
Dalamaga, M., Karmaniolas, K., Papadavid, E., Pelekanos, N., Sotiropoulos, G. and Lekka, A. (2011) Elevated Serum Visfatin/nicotinamide Phosphoribosyl-Transferase Levels Are Associated with Risk of Postmenopausal Breast Cancer Independently from Adiponectin, Leptin, and Anthropometric and Metabolic Parameters. Menopause, 18, 1198-1204. https://doi.org/10.1097/gme.0b013e31821e21f5
|
[96]
|
Dalamaga, M., Archondakis, S., Sotiropoulos, G., Karmaniolas, K., Pelekanos, N., Papadavid, E. and Lekka, A. (2012) Could Serum Visfatin Be a Potential Biomarker for Postmenopausal Breast Cancer. Maturitas, 71, 301-308. https://doi.org/10.1016/j.maturitas.2011.12.013
|
[97]
|
Li, X.Y., Tang, S.H., Zhou, X.C., Ye, Y.H., Xu, X.Q. and Li, R.Z. (2014) Preoperative Serum Visfatin Levels and Prognosis of Breast Cancer among Chinese Women. Peptides, 51, 86-90. https://doi.org/10.1016/j.peptides.2013.11.010
|
[98]
|
Hung, A.C., Lo, S., Hou, M.F., Lee, Y.C., Tsai, C.H., Chen, Y.Y., Liu, W., Su, Y.H., Lo, Y.H., Wang, C.H., Wu, S.C., Hsieh, Y.C., Hu, S.C., Tai, M.H., Wang, Y.M. and Yuan, S.S. (2016) Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through C-Abl and STAT3 Activation. Clinical Cancer Research, 22, 4478-4490. https://doi.org/10.1158/1078-0432.CCR-15-2704
|
[99]
|
Zhu, Y., Guo, M., Zhang, L., Xu, T., Wang, L. and Xu, G. (2016) Biomarker Triplet NAMPT/ VEGF/HER2 as a De Novo Detection Panel for the Diagnosis and Prognosis of Human Breast Cancer. Oncology Reports, 35, 454-462. https://doi.org/10.3892/or.2015.4391
|
[100]
|
Rodrigo, C., Tennekoon, K.H., Karunanayake, E.H., De Silva, K., Amarasinghe, I. and Wijayasiri, A. (2017) Circulating Leptin, Soluble Leptin Receptor, Free Leptin Index, Visfatin and Selected Leptin and Leptin Receptor Gene Polymorphisms in Sporadic Breast Cancer. Endocrine Journal, 64, 393-401. https://doi.org/10.1507/endocrj.EJ16-0448
|
[101]
|
Cymbaluk-PBoska, A., Chudecka-GBaz, A., Pius-Sadowska, E., Sompolska-RzechuBa, A., MachaliNski, B. and Menkiszak, J. (2018) Circulating Serum Level of Visfatin in Patients with Endometrial Cancer. BioMed Research International, January, 2018, Article ID: 8576179. https://doi.org/10.1155/2018/8576179
|
[102]
|
Ilhan, T., Kebapcilar, A. and Yilmaz, S. (2015) Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with Its Prognosis. Asian Pacific Journal of Cancer Prevention, 16, 4503-4508. https://doi.org/10.7314/APJCP.2015.16.11.4503
|
[103]
|
Avcioglu, S., Altinkaya, S., Küçük, M., Yüksel, H., Ömürlü, I. and Yanik, S. (2015) Visfatin Concentrations in Patients with Endometrial Cancer. Gynecological Endocrinology, 31, 202-207. https://doi.org/10.3109/09513590.2014.975687
|
[104]
|
Tian, W., Zhu, Y. and Wang, Y. (2013) Visfatin, a Potential Biomarker and Prognostic Factor for Endometrial Cancer. Gynecologic Oncology, 129, 505-512. https://doi.org/10.1016/j.ygyno.2013.02.022
|
[105]
|
Tian, W.Y., Wang, Y.M., Zhang, Y.F. and Xue, F.X. (2017) The Research Advances in the Relationship between Visfatin and Cancer. Chinese Journal of Oncology, 39, 321-324.
|
[106]
|
Fazeli, M.S., Dashti, H., Akbarzadeh, S., Assadi, M., Aminian, A., Keramati, M.R. and Nabipour, I. (2013) Circulating Levels of Novel Adipocytokines in Patients with Colorectal Cancer. Cytokine, 62, 81-85. https://doi.org/10.1016/j.cyto.2013.02.012
|
[107]
|
Sun, Y., Zhu, S., Wu, Z., Huang, Y., Liu, C., Tang, S. and Wei, L. (2017) Elevated Serum Visfatin Levels Are Associated with Poor Prognosis of Hepatocellular Carcinoma. Oncotarget, 8, 23427-23435. https://doi.org/10.18632/oncotarget.15080
|
[108]
|
Ninomiya, S., Shimizu, M., Imai, K., Takai, K., Shiraki, M., Hara, T., Tsurumi, H., Ishizaki, S. and Moriwaki, H. (2011) Possible Role of Visfatin in Hepatoma Progression and the Effects of Branched-Chain Amino Acids on Visfatin-Induced Proliferation in Human Hepatoma Cells. Cancer Prevention Research, 4, 2092-2100. https://doi.org/10.1158/1940-6207.CAPR-11-0340
|
[109]
|
Luhn, P., Dallal, C. and Weiss, J. (2013) Circulating Adipokine Levels and Endometrial Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiology, 22, 1304-1312. https://doi.org/10.1158/1055-9965.EPI-13-0258
|
[110]
|
Lu, G.W., Wang, Q.J., Xia, M.M. and Qian, J. (2014) Elevated Plasma Visfatin Levels Correlate with Poor Prognosis of Gastric Cancer Patients. Peptides, 58, 60-64. https://doi.org/10.1016/j.peptides.2014.05.016
|
[111]
|
Sourra, E.N., Sevastou, A., Villiotou, V. and Karikas, G.A. (2015) Correlation of Serum Lipid Concentrations in Patients with Acute Lymphoblastic Leukemia. Epitheorisi Klinikes Farmacologias Kai Farmakokinetikis, 33, 25.
|